Premium
Assessment of cardiac troponin I ( cTnI ) and tissue velocity imaging ( TVI ) in 14 dogs with malignant lymphoma undergoing chemotherapy treatment with doxorubicin
Author(s) -
Tater G.,
Eberle N.,
Hungerbuehler S.,
Joetzke A.,
Nolte I.,
Wess G.,
Betz D.
Publication year - 2017
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/vco.12135
Subject(s) - troponin i , doxorubicin , medicine , lymphoma , chemotherapy , canine lymphoma , troponin , cardiology , pathology , myocardial infarction
Doxorubicin has been shown to be cardiotoxic at high doses but is an efficacious chemotherapeutic agent in the treatment of canine lymphoma. Echocardiographic measurements and serum ultrasensitive cardiac troponin I ( cTnI ) levels were obtained before and after doxorubicin administration in 14 dogs diagnosed with lymphoma. The aim of this prospective study was to evaluate changes in cTnI concentrations and tissue velocity imaging ( TVI ) values in dogs with lymphoma undergoing chemotherapy with doxorubicin. A total of 182 cTnI and 1017 TVI measurements were performed. Standard echocardiographic parameters, tissue Doppler indices and cTnI concentrations did not differ at any time point within a 12‐week cyclic combination protocol. In conclusion, the use of doxorubicin at standard doses in the treatment of canine lymphoma may not be associated with significant myocardial damage.